Mean alerts per month per CCG/practice
|
(2.5)
|
(2.4)
|
(1.3)
|
(1.4)
|
Mean %, all measures
|
7.7
|
7.5
|
3.9
|
4.3
|
Topical treatment of fungal nail infections
|
5.3
|
6.2
|
2.1
|
2.9
|
High-cost PPIs
|
7.2
|
7.2
|
3.1
|
3.9
|
High cost tramadol preparations
|
2.4
|
3.3
|
4.6
|
4.4
|
High-cost drugs for erectile dysfunction
|
6.2
|
6.7
|
3.7
|
4.4
|
High-cost ARBs
|
6.7
|
4.3
|
2.7
|
2.7
|
High dose inhaled corticosteroids
|
14.4
|
12.9
|
5.8
|
5.1
|
Prescribing of dipyridamole
|
7.7
|
7.7
|
5.0
|
5.0
|
Methotrexate 10 mg tablets
|
5.3
|
7.7
|
2.7
|
3.1
|
Vitamin B complex
|
16.3
|
8.6
|
5.0
|
5.0
|
Soluble/effervescent forms of paracetamol and co-codamol
|
6.7
|
3.3
|
4.0
|
4.2
|
Non-preferred NSAIDs and COX-2 inhibitors
|
2.9
|
4.3
|
3.4
|
4.4
|
Other lipid-modifying drugs
|
8.1
|
6.7
|
4.7
|
3.9
|
Direct Oral Anticoagulants (DOACs)
|
14.4
|
15.3
|
4.5
|
4.9
|
Silver dressings
|
5.3
|
5.7
|
2.8
|
3.2
|
Long-acting insulin analogues
|
6.7
|
7.7
|
3.2
|
3.9
|
Volume of antibiotic prescribing
|
5.3
|
4.8
|
4.9
|
5.0
|
Prescribing of pregabalin
|
12.0
|
12.9
|
5.6
|
5.4
|
Diltiazem preparations prescribed generically
|
12.0
|
12.4
|
4.0
|
6.6
|
Co-proxamol
|
8.1
|
5.3
|
1.0
|
4.6
|
High dose opioids
|
4.8
|
6.2
|
5.8
|
5.5
|
Ciclosporin and tacrolimus oral preparations prescribed generically
|
2.9
|
5.7
|
1.4
|
2.2
|
Desogestrel prescribed as a branded product
|
11.5
|
12.4
|
4.6
|
6.2
|
Nebivolol 2.5mg tablets
|
7.2
|
6.7
|
3.1
|
2.6
|
Three-day antibiotic courses for UTIs
|
3.8
|
2.9
|
2.9
|
3.5
|
High-cost ACE inhibitors
|
2.4
|
2.4
|
1.7
|
3.0
|
High-cost statins
|
4.8
|
8.6
|
3.4
|
3.9
|
Glaucoma eye drops prescribed by brand
|
12.0
|
9.1
|
4.0
|
4.8
|
Higher dose Proton Pump Inhibitors
|
14.8
|
12.9
|
7.1
|
8.3
|
Co-amoxiclav, cephalosporins & quinolones
|
11.0
|
8.6
|
4.6
|
4.8
|
Extended-release quetiapine
|
11.5
|
7.7
|
6.2
|
5.9
|
Short acting beta agonist inhalers
|
3.8
|
8.6
|
3.5
|
3.0
|
Keppra vs. levetiracetam
|
5.3
|
4.3
|
3.3
|
2.7
|